Phase 2a trial in 91 adults with psoriatic arthritis after TNF inhibitor failure: guselkumab plus golimumab did not significantly improve week-24 minimal disease activity vs guselkumab alone (29% vs 22%; OR 1.4; P=0.557). Secondary ACR50 was 44% vs 22%.
RCTn = 91
Scher et al. Combination Therapy in Participants With Active Psoriatic Arthritis Using Subcutaneous Guselkumab and Golimumab: Week 24 Results From a Phase 2a, Multicenter, Randomized, Double-Blind, Proof-of-Concept Study